Clinical trials: Autoimmune Diseases
Bullous Pemphigoid
Rituximab in the Treatment of Patients With Bullous Pemphigoid
This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.
- Trial name
- NCT00286325
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
Down Syndrome, Polyendocrinopathies, Autoimmune
Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome
This study plans to learn more about Down syndrome. The investigators think there is a different level of the AIRE gene in individuals with Down syndrome.
- Conditions
- Down Syndrome, Polyendocrinopathies, Autoimmune, Respiratory Tract Infections, Autoimmunity
- Trial name
- NCT02421276
- Testing
- Phlebotomy
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Purpura, Thrombocytopenic, Idiopathic
Efficacy and Safety of IVIG-L in ITP Patients
The efficacy and safety of a liquid intravenous immunoglobulin product, IVIG-L, in patients with ITP will be assessed and compared with data obtained from literature.
- Trial name
- NCT00151840
- Testing
- IVIG-L
- Where
- 6 sites in Poland
- Volunteers
- 20 people
- Sponsor
- Prothya Biosolutions
Multiple Sclerosis
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
- Trial name
- SurfSubQ (NCT06780150)
- Testing
- Ocrelizumab
- Where
- 93 sites in Germany, Switzerland
- Volunteers
- 842 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers
Primary Objective: To demonstrate that sarilumab (SAR153191/REGN88) on top of methotrexate (MTX) was superior in efficacy to placebo for the relief of signs and symptoms of rheumatoid arthritis (RA), in participants with active…
- Trial name
- NCT01217814
- Testing
- Sarilumab, Golimumab, methotrexate (MTX)
- Where
- 14 sites in United States, Colombia and 4 more
- Volunteers
- 16 people
- Sponsor
- Sanofi
Lupus Nephritis
Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis
The purpose of this study is to assess the efficacy and safety of multi-target therapy in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ lupus nephritis.
- Trial name
- NCT00876616
- Testing
- Tacrolimus+Mycophenolate mofetil, Cyclophosphamide
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Zhi-Hong Liu, M.D.
IgA Nephropathy
Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis
The purpose of this study is to: 1. To evaluate the latest effects of TW for IgA nephropathy (IgAN) with asymptomatic abnormal urinalysis. 2. To evaluate the safety and tolerability of TW.
- Trial name
- NCT00885547
- Testing
- tripterygium wilfordii (TW)
- Volunteers
- 90 people
- Sponsor
- Nanjing University School of Medicine
Multiple Sclerosis, Quality of Life
Creating Satisfying Engagement in Daily Life Through Coaching for People With Multiple Sclerosis
Multiple sclerosis (MS) is a complex disease that negatively impacts a person's ability to participate in a wide range of important and meaningful activities1-4.
- Trial name
- NCT04908085
- Testing
- Occupational Performance Coaching
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Dorothy Kessler
Multiple Sclerosis (MS) - Relapsing-remitting
The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study
This pilot study aims to investigate the tolerability and feasibility of using metformin as an adjuvant treatment for RRMS. Also, it aims to evaluate the preliminary evidence of its efficacy by analyzing outcomes related to…
- Trial name
- NCT06812585
- Testing
- Metformin (Cidophage®), Usual Care
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- German University in Cairo
PARKINSON DISEASE (Disorder), Multiple Sclerosis
Cognitive Recovery Via Sensor-based Robotic Upper Limb Rehabilitation in Neurological Disorders
The goal of this clinical trial is to learn if sensor-based robotic upper limb rehabilitation can improve cognitive and motor functions in adults with neurological and neurodegenerative disorders, including Parkinson's disease…
- Conditions
- PARKINSON DISEASE (Disorder), Multiple Sclerosis, Stroke, Neurological Disorders
- Trial name
- CROSS-ND (NCT07384143)
- Testing
- Sensor-Based Robotic Rehabilitation with Cognitive Tasks (SBRR), Standard Conventional Therapy
- Where
- Italy
- Volunteers
- 189 people
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Diabetes Mellitus, Type 1
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a…
- Trial name
- NCT05904743
- Testing
- Afrezza, insulin degludec, Rapid-acting Insulin Analog
- Where
- 19 sites in United States
- Volunteers
- 141 people
- Sponsor
- Mannkind Corporation
Systemic Lupus Erythematosus
ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy and safety of ILT-101 (human recombinant interleukin 2 (IL-2)) in patients with moderate to severe systemic lupus erythematosus.
- Trial name
- LUPIL-2 (NCT02955615)
- Testing
- ILT-101
- Where
- 25 sites in Austria, Bulgaria and 8 more
- Volunteers
- 100 people
- Sponsor
- Iltoo Pharma
Rheumatoid Arthritis
Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
The condition that will be studied is Rheumatoid Arthritis (RA), and in particular, RA patients with moderate to highly active disease who were prescribed Abatacept (Orencia®) (ABA) by their physician during their setting of care…
- Trial name
- NCT05782335
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
Rheumatoid Arthritis
A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis
The primary objective of this study is to evaluate if baseline levels of T cell associated biomarkers predict efficacy of abatacept during 24 weeks of treatment in patients with moderate to severe active Rheumatoid Arthritis (RA)…
- Trial name
- NCT03882008
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
Diabete Type 1
The T1DWATCH Study: a Screening for Type 1 Diabetes Autoantibodies in Children for Early Detection and Intervention.
This study aims to identify early-stage type 1 diabetes (T1D) in children aged 2-6 and 8-10 years through autoantibody (Ab) screening, genetic and immunological analyses, and to evaluate the effectiveness of educational…
- Trial name
- T1DWATCH (NCT07492550)
- Volunteers
- 2,200 people
- Sponsor
- Fabiana Sherine Ganem dos Santos
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Effect of Paired Testing to Poorly Controlled Chinese Diabetes on Glycemic Control and Self Care
This study aims is to evaluate the effect of introducing paired testing on actual testing frequency, glycemic control, psychosocial and behavioural aspects of poorly controlled diabetes patients in China.
- Trial name
- NCT02225691
- Testing
- Paired testing of blood glucose Accu-Chek®
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Shanghai 6th People's Hospital
Rheumatoid Arthritis
ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis
ISIS 104838 is an antisense oligonucleotide drug that reduces the production of a specific protein called tumor necrosis factor (TNF-alpha), a substance that contributes to joint pain and swelling in rheumatoid arthritis.
- Trial name
- NCT00048321
- Testing
- ISIS 104838
- Where
- 31 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Rheumatoid Arthritis
More Added Value of Therapeutic Education in the Management of Patients With Rheumatoid Arthritis (ETP-PR)
Taking into account the recommendations of the Health Authority [1] and the application of patients' associations, we have structured a course of therapeutic education includes three stages for patients with rheumatoid arthritis…
- Trial name
- ETP-PR (NCT01564147)
- Testing
- immediate therapeutic education, therapeutic education delayed
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Nantes University Hospital
Multiple Sclerosis, NMO Spectrum Disorder
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Radiologically Isolated Syndrome
- Trial name
- RECLAIM (NCT06280755)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- icometrix
Systemic Lupus Erythematosus
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
The purpose of this study is to determine the ability of XmAb5871 to maintain Systemic Lupus Erythematosus (SLE) disease activity improvement achieved by a brief course of disease-suppressing steroid therapy
- Trial name
- NCT02725515
- Testing
- XmAb5871
- Where
- 23 sites in United States
- Volunteers
- 105 people
- Sponsor
- Xencor, Inc.